Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyImmunotherapy for Sarcoma: A Work in Progress

Meaningful advances in sarcoma treatment have been painfully slow. Modern immunotherapy may change that. The article referenced by this editorial reports the results of CMB305 plus atezolizumab or atezolizumab alone in patients with NY-ESO-1–expressing synovial or myxoid round cell liposarcoma. The relevance of this study furthers the data using novel immunotherapeutic strategies, which generate B- and T-cell responses for two rare sarcomas that can serve as a foundation for future trials.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form